CY1125102T1 - Αντιγονοδεσμευτικες πρωτεϊνες που ενεργοποιουν τον υποδοχεα λεπτινης - Google Patents
Αντιγονοδεσμευτικες πρωτεϊνες που ενεργοποιουν τον υποδοχεα λεπτινηςInfo
- Publication number
- CY1125102T1 CY1125102T1 CY20221100249T CY221100249T CY1125102T1 CY 1125102 T1 CY1125102 T1 CY 1125102T1 CY 20221100249 T CY20221100249 T CY 20221100249T CY 221100249 T CY221100249 T CY 221100249T CY 1125102 T1 CY1125102 T1 CY 1125102T1
- Authority
- CY
- Cyprus
- Prior art keywords
- antigen
- lepr
- binding fragments
- leptin
- bind
- Prior art date
Links
- 102000005861 leptin receptors Human genes 0.000 title abstract 8
- 108010019813 leptin receptors Proteins 0.000 title abstract 8
- 102000025171 antigen binding proteins Human genes 0.000 title 1
- 108091000831 antigen binding proteins Proteins 0.000 title 1
- 239000000427 antigen Substances 0.000 abstract 7
- 102000036639 antigens Human genes 0.000 abstract 7
- 108091007433 antigens Proteins 0.000 abstract 7
- 239000012634 fragment Substances 0.000 abstract 6
- 102000016267 Leptin Human genes 0.000 abstract 4
- 108010092277 Leptin Proteins 0.000 abstract 4
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 abstract 4
- 229940039781 leptin Drugs 0.000 abstract 4
- 230000011664 signaling Effects 0.000 abstract 3
- 101001129927 Homo sapiens Leptin receptor Proteins 0.000 abstract 1
- 206010049287 Lipodystrophy acquired Diseases 0.000 abstract 1
- 206010070834 Sensitisation Diseases 0.000 abstract 1
- 230000007812 deficiency Effects 0.000 abstract 1
- 230000002950 deficient Effects 0.000 abstract 1
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 102000007318 human leptin receptor Human genes 0.000 abstract 1
- 208000006132 lipodystrophy Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000008313 sensitization Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Neurosurgery (AREA)
- Reproductive Health (AREA)
- Child & Adolescent Psychology (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Η παρούσα εφεύρεση παρέχει αντισώματα και θραύσματα δέσμευσης αντιγόνου αυτών τα οποία δεσμεύουν τον ανθρώπινο υποδοχέα λεπτίνης (LEPR), και μέθοδοι για χρήση αυτών. Σύμφωνα με ορισμένες υλοποιήσεις, η εφεύρεση συμπεριλαμβάνει αντισώματα και θραύσματα δέσμευσης αντιγόνου αυτών τα οποία δεσμεύουν τον LEPR και ενεργοποιούν τη σηματοδότηση LEPR. Σε άλλες υλοποιήσεις, η εφεύρεση συμπεριλαμβάνει αντισώματα και θραύσματα δέσμευσης αντιγόνου αυτών τα οποία δεσμεύουν τον LEPR και αυξάνουν την ευαισθητοποίηση του LEPR σε ένα αντιγόνο. Σε ορισμένες υλοποιήσεις, η εφεύρεση συμπεριλαμβάνει αντισώματα και θραύσματα δέσμευσης αντιγόνου αυτών τα οποία δεσμεύουν τον LEPR στην απουσία και παρουσία λεπτίνης. Σε ορισμένες υλοποιήσεις, η εφεύρεση συμπεριλαμβάνει αντισώματα και θραύσματα δέσμευσης αντιγόνου αυτών τα οποία προκαλούν τη σηματοδότηση σε κύτταρα που εκφράζουν μεταλλαγμένα LEPR τα οποία επιδεικνύουν ελαττωματική ή μειωμένη σηματοδότηση με άλλο τρόπο στην παρουσία λεπτίνης. Τα αντισώματα και θραύσματα δέσμευσης αντιγόνου της παρούσας εφεύρεσης είναι χρήσιμα για την θεραπεία λιποδυστροφίας και άλλων ασθενειών και διαταραχών τα οποία σχετίζονται με ή προκαλούνται από έλλειψη λεπτίνης ή αντίσταση στη λεπτίνη.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562240021P | 2015-10-12 | 2015-10-12 | |
US201662359757P | 2016-07-08 | 2016-07-08 | |
US201662375495P | 2016-08-16 | 2016-08-16 | |
US201662393143P | 2016-09-12 | 2016-09-12 | |
PCT/US2016/056465 WO2017066204A1 (en) | 2015-10-12 | 2016-10-11 | Antigen-binding proteins that activate the leptin receptor |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1125102T1 true CY1125102T1 (el) | 2024-02-16 |
Family
ID=57184864
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20221100249T CY1125102T1 (el) | 2015-10-12 | 2022-03-31 | Αντιγονοδεσμευτικες πρωτεϊνες που ενεργοποιουν τον υποδοχεα λεπτινης |
Country Status (32)
Country | Link |
---|---|
US (5) | US10023644B2 (el) |
EP (2) | EP3362477B1 (el) |
JP (5) | JP7034068B2 (el) |
KR (1) | KR20180070609A (el) |
CN (1) | CN108368177B (el) |
AU (2) | AU2016338851B2 (el) |
BR (1) | BR112018007318A2 (el) |
CA (1) | CA3000215A1 (el) |
CL (2) | CL2018000946A1 (el) |
CO (1) | CO2018003852A2 (el) |
CY (1) | CY1125102T1 (el) |
DK (1) | DK3362477T3 (el) |
EA (1) | EA201890928A1 (el) |
ES (1) | ES2908574T3 (el) |
HK (1) | HK1254862A1 (el) |
HR (1) | HRP20220426T8 (el) |
HU (1) | HUE058280T2 (el) |
IL (2) | IL300961A (el) |
LT (1) | LT3362477T (el) |
MX (2) | MX2018004531A (el) |
MY (1) | MY187975A (el) |
PH (1) | PH12018500663A1 (el) |
PL (1) | PL3362477T3 (el) |
PT (1) | PT3362477T (el) |
RS (1) | RS63061B1 (el) |
SG (1) | SG10201913432RA (el) |
SI (1) | SI3362477T1 (el) |
TW (3) | TWI752920B (el) |
UA (1) | UA124419C2 (el) |
UY (1) | UY36942A (el) |
WO (1) | WO2017066204A1 (el) |
ZA (1) | ZA201801975B (el) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI752920B (zh) | 2015-10-12 | 2022-01-21 | 美商再生元醫藥公司 | 活化瘦素受體的抗原結合蛋白 |
KR102563568B1 (ko) * | 2016-11-08 | 2023-08-04 | 리제너론 파마슈티칼스 인코포레이티드 | 렙틴 수용체에 길항하는 항원-결합 단백질 |
MX2020006508A (es) * | 2017-12-18 | 2020-09-17 | Regeneron Pharma | Moleculas de union a antigeno biespecificas que se unen al receptor de leptina y/o gp130, y metodos para el uso de estas. |
CA3094400A1 (en) * | 2018-04-06 | 2019-10-10 | Regeneron Pharmaceuticals, Inc. | A leptin receptor agonist antibody for use in treating a metabolic dysfunction or hypoleptinemia |
CN112789268A (zh) * | 2018-10-11 | 2021-05-11 | 住友化学株式会社 | 环氧丙烷纯化装置和环氧丙烷的制造方法 |
JP2022519534A (ja) * | 2019-01-31 | 2022-03-24 | シーメンス・ヘルスケア・ダイアグノスティックス・インコーポレイテッド | 抗ナロキソンおよび抗ナルトレキソンモノクローナル抗体ならびにその作製方法および使用方法 |
US20220275097A1 (en) * | 2019-07-02 | 2022-09-01 | Shanghaitech University | Antibody to leptin receptor |
WO2021111156A1 (en) | 2019-12-03 | 2021-06-10 | Micron Technology, Inc. | Cache architecture for a storage device |
KR20210095781A (ko) | 2020-01-24 | 2021-08-03 | 주식회사 에이프릴바이오 | 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물 |
AU2021343444A1 (en) * | 2020-09-15 | 2023-04-20 | Regeneron Pharmaceuticals, Inc. | Use of lepr agonists for pain |
JP2024512255A (ja) | 2021-02-22 | 2024-03-19 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 部分性脂肪萎縮症を診断および処置するための方法 |
CN114456124B (zh) * | 2021-12-30 | 2023-04-21 | 华南农业大学 | 一种新利司他半抗原、人工抗原、抗体及其制备方法和应用 |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5643748A (en) | 1994-09-14 | 1997-07-01 | Progenitor, Inc. | HU-B1.219, a novel human hematopoietin receptor |
US5856098A (en) | 1994-09-14 | 1999-01-05 | Progenitor, Inc. | Detection of a leptin receptor variant |
US5912123A (en) | 1994-09-14 | 1999-06-15 | Progenitor, Inc. | Detection of the leptin receptor in reproductive organs and methods for regulating reproductive biology |
US6451523B1 (en) | 1994-09-14 | 2002-09-17 | Interneuron Pharmaceuticals, Inc. | Detection of a leptin receptor variant and methods for regulating obesity |
US6482927B1 (en) | 1995-11-27 | 2002-11-19 | Millennium Pharmaceuticals, Inc. | Chimeric proteins comprising the extracellular domain of murine Ob receptor |
US6977240B1 (en) * | 1995-11-27 | 2005-12-20 | Millenium Pharmaceuticals, Inc. | Methods of using the OB receptor antibodies to treat bodyweight disorders |
CA2241564C (en) | 1996-01-08 | 2013-09-03 | Genentech, Inc. | Wsx receptor and ligands |
US20050019325A1 (en) | 1996-01-08 | 2005-01-27 | Carter Paul J. | WSX receptor agonist antibodies |
AU2476301A (en) | 1996-01-16 | 2001-05-24 | Rockefeller University, The | DB the receptor for leptin nucleic acids encoding the receptor, and uses thereof |
AU1833197A (en) | 1996-01-18 | 1997-08-11 | Progenitor, Inc. | Detection of a leptin receptor variant and methods for regulating obesity |
CA2244693A1 (en) | 1996-01-23 | 1997-07-31 | Progenitor, Inc. | Methods for using the obese gene and its gene product to stimulate hematopoietic development |
AUPN780096A0 (en) | 1996-01-30 | 1996-02-22 | Medvet Science Pty. Ltd. | Cytokine antagonists and agonists |
IL120733A0 (en) | 1997-04-29 | 1997-08-14 | Yeda Res & Dev | Leptin as an inhibitor of cell proliferation |
JP2005516001A (ja) | 2001-12-05 | 2005-06-02 | ベイラー カレッジ オブ メディスン | 交感神経活動状態の調節による骨形成の制御のための方法及び組成物 |
DE10353593A1 (de) | 2003-11-17 | 2005-06-23 | Klinikum der Universität München Großhadern-Innenstadt | Leptinantagonist und Verfahren zur quantitativen Messung von Leptin |
US20070281327A1 (en) | 2003-12-12 | 2007-12-06 | Kiyotaka Nakano | Methods of Screening for Modified Antibodies With Agonistic Activities |
US7863240B2 (en) | 2004-10-08 | 2011-01-04 | Enzo Therapeutics, Inc. | Methods and uses of leptin in hepatocellular carcinoma |
US8969291B2 (en) | 2004-10-08 | 2015-03-03 | Enzo Therapeutics, Inc. | Methods for decreasing leptin levels or activity for treating inflammation |
EP1812038A1 (en) | 2004-11-18 | 2007-08-01 | VIB vzw | Fibronectin iii domain as leptin receptor antagonists |
WO2006116260A2 (en) | 2005-04-26 | 2006-11-02 | Medimmune, Inc. | Modulation of antibody effector function by hinge domain engineering |
WO2008140603A2 (en) | 2006-12-08 | 2008-11-20 | Macrogenics, Inc. | METHODS FOR THE TREATMENT OF DISEASE USING IMMUNOGLOBULINS HAVING FC REGIONS WITH ALTERED AFFINITIES FOR FCγR ACTIVATING AND FCγR INHIBITING |
JO3756B1 (ar) * | 2010-11-23 | 2021-01-31 | Regeneron Pharma | اجسام مضادة بشرية لمستقبلات الجلوكاجون |
EA035987B1 (ru) | 2012-09-12 | 2020-09-09 | Джензим Корпорейшн | ПОЛИПЕПТИДЫ, СОДЕРЖАЩИЕ Fc С ИЗМЕНЕННЫМ ГЛИКОЗИЛИРОВАНИЕМ И СНИЖЕННОЙ АФФИННОСТЬЮ К Fc-ГАММА РЕЦЕПТОРАМ |
TWI635098B (zh) | 2013-02-01 | 2018-09-11 | 再生元醫藥公司 | 含嵌合恆定區之抗體 |
TW201920262A (zh) | 2013-07-30 | 2019-06-01 | 美商再生元醫藥公司 | 抗活化素a之抗體及其用途 |
JP6666848B2 (ja) | 2014-02-18 | 2020-03-18 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | Nrp−1/obr複合体シグナル伝達経路により媒介される疾患の処置のための方法及び医薬組成物 |
TWI752920B (zh) | 2015-10-12 | 2022-01-21 | 美商再生元醫藥公司 | 活化瘦素受體的抗原結合蛋白 |
MX2020006508A (es) | 2017-12-18 | 2020-09-17 | Regeneron Pharma | Moleculas de union a antigeno biespecificas que se unen al receptor de leptina y/o gp130, y metodos para el uso de estas. |
-
2016
- 2016-10-07 TW TW105132493A patent/TWI752920B/zh active
- 2016-10-07 TW TW112125041A patent/TW202417497A/zh unknown
- 2016-10-07 TW TW111100429A patent/TWI824372B/zh active
- 2016-10-11 LT LTEPPCT/US2016/056465T patent/LT3362477T/lt unknown
- 2016-10-11 ES ES16785072T patent/ES2908574T3/es active Active
- 2016-10-11 CA CA3000215A patent/CA3000215A1/en active Pending
- 2016-10-11 DK DK16785072.6T patent/DK3362477T3/da active
- 2016-10-11 BR BR112018007318A patent/BR112018007318A2/pt active Search and Examination
- 2016-10-11 MX MX2018004531A patent/MX2018004531A/es unknown
- 2016-10-11 HU HUE16785072A patent/HUE058280T2/hu unknown
- 2016-10-11 US US15/290,967 patent/US10023644B2/en active Active
- 2016-10-11 IL IL300961A patent/IL300961A/en unknown
- 2016-10-11 EP EP16785072.6A patent/EP3362477B1/en active Active
- 2016-10-11 UY UY0001036942A patent/UY36942A/es not_active Application Discontinuation
- 2016-10-11 EA EA201890928A patent/EA201890928A1/ru unknown
- 2016-10-11 EP EP21207469.4A patent/EP4071173A1/en active Pending
- 2016-10-11 JP JP2018518592A patent/JP7034068B2/ja active Active
- 2016-10-11 RS RS20220294A patent/RS63061B1/sr unknown
- 2016-10-11 KR KR1020187013185A patent/KR20180070609A/ko not_active Application Discontinuation
- 2016-10-11 AU AU2016338851A patent/AU2016338851B2/en active Active
- 2016-10-11 CN CN201680072173.1A patent/CN108368177B/zh active Active
- 2016-10-11 WO PCT/US2016/056465 patent/WO2017066204A1/en active Application Filing
- 2016-10-11 UA UAA201803447A patent/UA124419C2/uk unknown
- 2016-10-11 HR HRP20220426TT patent/HRP20220426T8/hr unknown
- 2016-10-11 PL PL16785072T patent/PL3362477T3/pl unknown
- 2016-10-11 SG SG10201913432RA patent/SG10201913432RA/en unknown
- 2016-10-11 SI SI201631477T patent/SI3362477T1/sl unknown
- 2016-10-11 PT PT167850726T patent/PT3362477T/pt unknown
- 2016-10-11 MY MYPI2018701183A patent/MY187975A/en unknown
-
2018
- 2018-03-26 PH PH12018500663A patent/PH12018500663A1/en unknown
- 2018-03-26 ZA ZA2018/01975A patent/ZA201801975B/en unknown
- 2018-03-29 IL IL258448A patent/IL258448B2/en unknown
- 2018-04-11 CO CONC2018/0003852A patent/CO2018003852A2/es unknown
- 2018-04-12 CL CL2018000946A patent/CL2018000946A1/es unknown
- 2018-04-12 MX MX2023000738A patent/MX2023000738A/es unknown
- 2018-06-13 US US16/007,848 patent/US10253102B2/en active Active
- 2018-06-13 US US16/007,812 patent/US10618968B2/en active Active
- 2018-11-01 HK HK18113959.2A patent/HK1254862A1/zh unknown
-
2019
- 2019-05-28 CL CL2019001434A patent/CL2019001434A1/es unknown
- 2019-10-04 US US16/593,761 patent/US20200031946A1/en not_active Abandoned
-
2021
- 2021-03-11 JP JP2021039405A patent/JP7165225B2/ja active Active
- 2021-11-30 US US17/539,034 patent/US20220112293A1/en active Pending
-
2022
- 2022-03-31 CY CY20221100249T patent/CY1125102T1/el unknown
- 2022-10-21 JP JP2022169008A patent/JP7436603B2/ja active Active
-
2023
- 2023-07-19 AU AU2023206125A patent/AU2023206125A1/en active Pending
- 2023-11-30 JP JP2023202680A patent/JP2024026230A/ja active Pending
-
2024
- 2024-02-09 JP JP2024018406A patent/JP2024042114A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1125102T1 (el) | Αντιγονοδεσμευτικες πρωτεϊνες που ενεργοποιουν τον υποδοχεα λεπτινης | |
CY1125260T1 (el) | Παραγοντες δεσμευσης tigit και χρησεις τους | |
CY1125267T1 (el) | Antiσωmata eiδiκως σynδeonta pd-1 kai xphσeiς aytωn | |
CY1124896T1 (el) | Αντισωματα κατα της αλφα-συνουκλεïνης και χρησεις αυτων | |
CY1121893T1 (el) | Μορια αντισωματος κατα της τιμ-3 και χρησεις αυτων | |
CY1120471T1 (el) | Αντισωματα κατα του cd70 | |
CY1123788T1 (el) | Αντισωματα αντι-ακτιβινης α και χρησεις αυτων | |
CY1123454T1 (el) | Πολυπεπτιδια me δυο παρατοπους τα οποια ανταγωνιζονται τη σηματοδοτηση wnt σε κυτταρα ογκων | |
CY1124118T1 (el) | Αντισωματα προσδεσης θυμικης στρωματικης λεμφοποιητινης (tslp) και μεθοδοι χρησης των αντισωματων | |
CY1124698T1 (el) | Πρωτεϊνη δεσμευσης il-18 (il-18bp) σε φλεγμονωδεις νοσους | |
CY1124778T1 (el) | Αντισωματα anti-asic1 και χρησεις αυτων | |
CY1124412T1 (el) | Aνti-dkk-1 αντισωματα | |
EA201890285A1 (ru) | Антитела против pd-1, активируемые антитела против pd-1 и способы их применения | |
EA201790755A1 (ru) | Модуляция стимулирующих и нестимулирующих миелоидных клеток | |
EA202090931A2 (ru) | Композиции и способы перепрограммирования tcr с помощью гибридных белков | |
BR112019024654A2 (pt) | proteína de ligação nkg2d, cd16 e ror1 ou ror2 | |
EA201692539A1 (ru) | Антитела и антигенсвязывающие фрагменты, которые специфично связываются с белком тау, ассоциированным с микротрубочками | |
CY1123781T1 (el) | Anti-tnf αλφα-αντισωματα και λειτουργικα θραυσματα αυτων | |
BR112018068678A2 (pt) | anticorpos anti-mica | |
PH12017500331A1 (en) | Antigen binding proteins that bind cxcr5 | |
CY1121347T1 (el) | Πρωτεϊνη συντηξης | |
CY1123275T1 (el) | Μορια συνδεσης ειδικα για il-21 και χρησεις αυτων | |
CY1123784T1 (el) | Αντισωματα enanti-tnf αλφα και λειτουργικα θραυσματα αυτων | |
EA201892063A1 (ru) | МОДИФИЦИРОВАННЫЕ ИММУНОГЛОБУЛИНЫ С ИЗМЕНЕННЫМ СВЯЗЫВАНИЕМ FcRn | |
CY1124445T1 (el) | Αντισωματα αντι-ccl17 |